IL-27 in combination with anti-PD-1 can be anti-cancer or pro-cancer
From MaRDI portal
(Redirected from Publication:6177320)
Recommendations
- Combination therapy for cancer with IL-27 and anti-PD-1: A simplified mathematical model
- The role of the cytokines IL-27 and IL-35 in cancer
- Mathematical modeling for the combination treatment of IFN-\(\gamma\) and anti-PD-1 in cancer immunotherapy
- Mathematical model for IL-2-based cancer immunotherapy
- Qualitative analysis and numerical simulations of new model describing cancer
Cites work
- A mathematical model of tumor-immune interactions
- A methodology for performing global uncertainty and sensitivity analysis in systems biology
- Mathematical model of sarcoidosis
- Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor
- Modelling the interactions between tumour cells and a blood vessel in a microenvironment within a vascular tumour
- The role of exosomes in pancreatic cancer microenvironment
Cited in
(3)- Modelling immune dynamics in locally advanced MSI-H/dMMR colorectal cancer with neoadjuvant pembrolizumab treatment: from differential equations to an agent-based framework
- Optimisation of neoadjuvant pembrolizumab therapy for locally advanced MSI-H/dMMR colorectal cancer using data-driven delay integro-differential equations
- Optimisation of pembrolizumab therapy for de novo metastatic MSI-H/dMMR colorectal cancer using data-driven delay integro-differential equations
This page was built for publication: IL-27 in combination with anti-PD-1 can be anti-cancer or pro-cancer
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6177320)